Cai Zihao, Meng Kelin, Yu Taiyan, Xi Yu, Yuan Zhiwei, Wang Xue, Wang Congjian, Li Lequn, Fu Xiangning
Thoracic Surgery Laboratory, Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, China.
Front Immunol. 2025 Apr 30;16:1551322. doi: 10.3389/fimmu.2025.1551322. eCollection 2025.
Tumor angiogenesis is a critical biological hallmark of cancer, which involves multiple molecularly regulated signaling pathways, including the angiopoietin (ANGPT)-Tie2 and the vascular endothelial growth factor (VEGF) signaling pathways. Despite initial optimism, targeting tumor angiogenesis in the treatment of lung adenocarcinoma (LUAD) has been unsatisfactory. Currently, monotherapy with PD-1/PD-L1 inhibitors, or their combination with bevacizumab, is considered the standard therapeutic approach for LUAD. Recent studies have shown that immunotherapy suppresses tumor angiogenesis and facilitates vascular normalization. However, whether and how anti-PD-L1 therapy influences tumor vasculature remains unclear.
To investigate the impact of immunotherapy on the vasculature of LUAD, a mouse model of lung adenocarcinoma was established by subcutaneous implantation of Lewis lung carcinoma cells . The effects of different treatments on microvessel density and pericyte coverage were explored, and the expression of angiogenesis-related factors was analyzed. Furthermore, to explore the molecular mechanisms through which IFN-γ regulates tumor blood vessels during immunotherapy, we elucidated the specific mechanisms by means of techniques such as siRNA, ChIP, RT-qPCR, Western blot, and immunofluorescence. Finally, the effects of IFN-γ on the proliferation, migration, and angiogenic function of endothelial cells (ECs) were evaluated through CCK-8, Transwell, and HUVEC tube formation assays.
Employing a mouse model of LUAD, we demonstrated that PD-L1 blockade therapy inhibits tumor angiogenesis and normalizes vasculature in an IFN-γ-signaling-dependent manner. Notably, anti-PD-L1 therapy reduced Tie2 and ANGPT2 expression, and these effects were reversed by the JAK1/2 inhibitor. Mechanistically, we demonstrated that IFN-γ inhibited Tie2 and ANGPT2 expression in ECs, and suppressed gene transcription through the AKT-FOXO1 signaling pathway. Interestingly, IFN-γ-mediated activation of STAT1 exerts negative regulation by directly binding to the promoter regions of the and genes. Functionally, IFN-γ limits the migration, proliferation, and tube formation of ECs.
In conclusion, our results revealed a novel mechanism wherein IFN-γ-mediated inhibition of ANGPT2-Tie2 facilitates vascular normalization during immunotherapy in LUAD, which performs an essential function in the antitumor efficacy of immunotherapy.
肿瘤血管生成是癌症的一个关键生物学特征,涉及多种分子调控的信号通路,包括血管生成素(ANGPT)-Tie2和血管内皮生长因子(VEGF)信号通路。尽管最初抱有乐观态度,但在肺腺癌(LUAD)治疗中靶向肿瘤血管生成的效果并不理想。目前,PD-1/PD-L1抑制剂单药治疗或其与贝伐单抗联合治疗被认为是LUAD的标准治疗方法。最近的研究表明,免疫疗法可抑制肿瘤血管生成并促进血管正常化。然而,抗PD-L1治疗是否以及如何影响肿瘤血管系统仍不清楚。
为了研究免疫疗法对LUAD血管系统的影响,通过皮下植入Lewis肺癌细胞建立了肺腺癌小鼠模型。探讨了不同治疗方法对微血管密度和周细胞覆盖的影响,并分析了血管生成相关因子的表达。此外,为了探究免疫治疗期间IFN-γ调节肿瘤血管的分子机制,我们通过siRNA、ChIP、RT-qPCR、蛋白质免疫印迹和免疫荧光等技术阐明了具体机制。最后,通过CCK-8、Transwell和人脐静脉内皮细胞(HUVEC)管形成试验评估了IFN-γ对内皮细胞(EC)增殖、迁移和血管生成功能的影响。
利用LUAD小鼠模型,我们证明PD-L1阻断疗法以IFN-γ信号依赖的方式抑制肿瘤血管生成并使血管系统正常化。值得注意的是,抗PD-L1治疗降低了Tie2和ANGPT2的表达,而这些作用被JAK1/2抑制剂逆转。从机制上讲,我们证明IFN-γ抑制EC中Tie2和ANGPT2的表达,并通过AKT-FOXO1信号通路抑制基因转录。有趣的是,IFN-γ介导的STAT1激活通过直接结合ANGPT2和Tie2基因的启动子区域发挥负调控作用。在功能上,IFN-γ限制了EC的迁移、增殖和管形成。
总之,我们的结果揭示了一种新机制,即IFN-γ介导的ANGPT2-Tie2抑制在LUAD免疫治疗期间促进血管正常化,这在免疫治疗的抗肿瘤疗效中发挥着重要作用。